Citadel Advisors’s Emmaus Life Sciences, Inc. Common Stock EMMA Stock Holding History

Citadel Advisors’s Portfolio EMMA Stock Details EMMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-11,237	Closed	-$49K	–	10217
2018 Q4	$49K	Buy	+11,237	New	+$90.2K	﹤0.01%	8496

Other funds holding EMMA

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

FFA

First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's EMMA Position: Q1 2019 in Review

Citadel Advisors sold out of Emmaus Life Sciences, Inc. Common Stock (EMMA) in Q1 2019, closing a stake of 11,237 shares — an estimated $49K sold.

Citadel Advisors first reported a position in EMMA in Q4 2018 and held it in 1 quarter. The position peaked at $49K in Q4 2018. 7 funds tracked by Wall St. Rank hold EMMA as of Q1 2019.

Citadel Advisors reported no remaining Emmaus Life Sciences, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Citadel Advisors sold 11,237 Emmaus Life Sciences, Inc. Common Stock shares in Q1 2019, an estimated $49K.
Citadel Advisors first reported a position in Emmaus Life Sciences, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
Citadel Advisors's Emmaus Life Sciences, Inc. Common Stock position peaked at $49K in Q4 2018.
7 funds tracked by Wall St. Rank held Emmaus Life Sciences, Inc. Common Stock as of Q1 2019.

Based on Citadel Advisors's 13F filing for Q1 2019, filed 15 May 2019.